Short answer... Nobody knows anything besides the leadership. I like the idea floating around that ENZC will own 60-90% of the new SAGA though.
As far as Samsung, I have long predicted that they want the whole shebang in a nice wrapped present, and will be happy to pay for it when all the ducks are in a row. Enzo would say yes to them because they have had Enzo's back.
As far as SAGA though, who knows if that will even go through? No extension notice is either a done deal or a collapsed deal.
Add the exclusive license agreement for ITV-1 to your list. I assume that would also transfer to SAGA. ENZC couldn't collect royalties or licensing fees because the patents are owned by The Zhabilov Trust.
From what I can see, ENZC would either get $250M cash to fund whatever it could do with RobustoMed, BioClonetics, International Medical Partners Ltd, and to cover its liabilities
Or some amount of equity in SAGA to be able to profit alongside SAGA which someday earns revenue from Biogenysis and Virogentics, assuming the tech is profitable. This second possibility might be better for ENZC shareholders since it could create ongoing value for ENZC.
Keep in mind Gaurav Chandra, Charles Cotropia, Joseph Cotropia, Suraj Saggar, and Kirsten Bischof would all have new roles under SAGA as well, per the recent PR. Will they have any capacity to also continue work for ENZC?
I would think SAGA would want their services full time, and exclusively, to avoid a conflict of interest. What would that mean for ENZC?
News 
Market Data 
Discover 
AI
